⌘K
t
GSK plc granted options over Ordinary Shares to three of its Persons Discharging Managerial Responsibilities (PDMRs) on 28 November 2025. SVP and Group General Counsel James Ford, President Corporate Development David Redfern, and SVP & Company Secretary Victoria Whyte each received 643 options at a price of £14.19, pursuant to the Company's Share Save Plan 2022 on the London Stock Exchange.
| Date | 1 Dec 2025 |
| Time | 15:30:00 |
| Category | Director/PDMR dealings |
| ID | 7266J |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
James Ford |
||||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
David Redfern |
||||
|
b) |
Position/status |
President, Corporate Development |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Victoria Whyte |
||||
|
b) |
Position/status |
SVP & Company Secretary |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG